38,148 Shares in Amicus Therapeutics, Inc. (NASDAQ:FOLD) Bought by Dark Forest Capital Management LP

Dark Forest Capital Management LP bought a new stake in Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) during the fourth quarter, according to its most recent filing with the SEC. The firm bought 38,148 shares of the biopharmaceutical company's stock, valued at approximately $359,000.

Other institutional investors have also recently bought and sold shares of the company. Covestor Ltd grew its position in shares of Amicus Therapeutics by 114.9% in the fourth quarter. Covestor Ltd now owns 4,325 shares of the biopharmaceutical company's stock valued at $41,000 after purchasing an additional 2,312 shares during the last quarter. R Squared Ltd bought a new stake in Amicus Therapeutics during the 4th quarter valued at approximately $79,000. Virtu Financial LLC acquired a new stake in Amicus Therapeutics in the 3rd quarter valued at approximately $107,000. KBC Group NV increased its position in Amicus Therapeutics by 44.4% in the 4th quarter. KBC Group NV now owns 10,154 shares of the biopharmaceutical company's stock worth $96,000 after buying an additional 3,120 shares during the period. Finally, Sciencast Management LP acquired a new position in shares of Amicus Therapeutics during the fourth quarter worth approximately $100,000.

Amicus Therapeutics Trading Up 2.1 %

Shares of FOLD opened at $7.35 on Monday. The stock has a 50 day simple moving average of $8.16 and a 200-day simple moving average of $9.39. Amicus Therapeutics, Inc. has a 1 year low of $6.20 and a 1 year high of $12.65. The stock has a market cap of $2.26 billion, a PE ratio of -40.83, a PEG ratio of 1.51 and a beta of 0.79. The company has a current ratio of 3.39, a quick ratio of 2.42 and a debt-to-equity ratio of 2.01.

Analyst Ratings Changes

Several equities analysts recently commented on FOLD shares. StockNews.com cut shares of Amicus Therapeutics from a "buy" rating to a "hold" rating in a research note on Thursday, February 20th. Needham & Company LLC reaffirmed a "hold" rating on shares of Amicus Therapeutics in a research report on Thursday, February 20th. Cantor Fitzgerald reissued an "overweight" rating and set a $21.00 target price on shares of Amicus Therapeutics in a research report on Wednesday, January 15th. Finally, Wells Fargo & Company lowered their price target on Amicus Therapeutics from $18.00 to $17.00 and set an "overweight" rating on the stock in a research note on Thursday, February 20th. Three research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $16.75.

Amicus Therapeutics Company Profile

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.

Want to see what other hedge funds are holding FOLD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.